230 related articles for article (PubMed ID: 34709662)
1. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Zucker SD; Grover S
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1444-1452.e4. PubMed ID: 38401693
[TBL] [Abstract][Full Text] [Related]
3. Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Grover S; Zucker SD
J Natl Compr Canc Netw; 2023 Jun; 21(6):617-626.e3. PubMed ID: 37308118
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
6. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
7. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
8. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study.
Lee MD; Seethapathy H; Strohbehn IA; Zhao SH; Boland GM; Fadden R; Sullivan R; Reynolds KL; Sise ME
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849926
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit.
Yaqoob H; Greenberg D; Hwang F; Lee C; Vernik D; Manglani R; Wang Z; Murad MH; Chandy D; Epelbaum O
J Med Virol; 2022 Jan; 94(1):349-356. PubMed ID: 34542192
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
11. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis.
Weber S; Benesic A; Rotter I; Gerbes AL
Liver Int; 2019 Oct; 39(10):1906-1917. PubMed ID: 31319011
[TBL] [Abstract][Full Text] [Related]
12. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
Favara DM; Spain L; Au L; Clark J; Daniels E; Diem S; Chauhan D; Turajlic S; Powell N; Larkin JM; Yousaf N
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32641348
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure.
Wong GL; Wong VW; Yuen BW; Tse YK; Yip TC; Luk HW; Lui GC; Chan HL
J Hepatol; 2020 Jan; 72(1):57-66. PubMed ID: 31499132
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.
Miller ED; Abu-Sbeih H; Styskel B; Nogueras Gonzalez GM; Blechacz B; Naing A; Chalasani N
Am J Gastroenterol; 2020 Feb; 115(2):251-261. PubMed ID: 31789632
[TBL] [Abstract][Full Text] [Related]
15. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review.
Lai KC; Hsiao YH; Chen SC
Front Immunol; 2022; 13():994064. PubMed ID: 36119082
[TBL] [Abstract][Full Text] [Related]
16. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
[TBL] [Abstract][Full Text] [Related]
17. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
[TBL] [Abstract][Full Text] [Related]
18. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.
Zhang L; Zlotoff DA; Awadalla M; Mahmood SS; Nohria A; Hassan MZO; Thuny F; Zubiri L; Chen CL; Sullivan RJ; Alvi RM; Rokicki A; Murphy SP; Jones-O'Connor M; Heinzerling LM; Barac A; Forrestal BJ; Yang EH; Gupta D; Kirchberger MC; Shah SP; Rizvi MA; Sahni G; Mandawat A; Mahmoudi M; Ganatra S; Ederhy S; Zatarain-Nicolas E; Groarke JD; Tocchetti CG; Lyon AR; Thavendiranathan P; Cohen JV; Reynolds KL; Fradley MG; Neilan TG
Circulation; 2020 Jun; 141(24):2031-2034. PubMed ID: 32539614
[No Abstract] [Full Text] [Related]
19. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Guo X; Li W; Hu J; Zhu EC; Su Q
Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
